Products
As of April 2022
| Brand Name | Launch | Indications | Licensor | |
|---|---|---|---|---|
| 1 | NOBELZIN® | Apr-08 | Wilson’s disease | Teva |
| 2 | LUNABELL® LD | Jul-08 | dysmenorrhea | Janssen |
| 3 | NOBELBAR® | Dec-08 | neonatal seizures, status epilepticus |
In-house/ Kagawa Univ |
| 4 | Fostoin® | Jan-12 | status epilepticus, prevention of postoperative seizures, etc. |
In-house |
| 5 | GLIADEL® | Jan-13 | malignant glioma | Eisai |
| 6 | INDACIN® | Jan-13 | patent ductus arteriosus of prematurity | Lundbeck |
| 7 | COSMEGEN® | Jan-13 | Wilms’ tumor, chorionepitelioma, pediatric solid malignant tumor, etc. |
Lundbeck |
| 8 | LUNABELL® ULD | Sep-13 | dysmenorrhea | Janssen |
| 9 | Alabel® | Sep-13 | diagnosis of malignant glioma | medac |
| 10 | Unitalc® | Dec-13 | prevention of recurrent malignant pleural effusion | Novatech/ Nagoya Medical Center |
| 11 | Respia® | Dec-14 | apnea of prematurity | Nippon Boehringer (co-development) |
| 12 | RAPALIMUS® | Dec-14 | lymphangioleiomyomatosis | Pfizer/ Niigata Univ |
| 13 | ZANOSAR® | Feb-15 | gastroenteropancreatic neuroendocrine tumor | Keocyt |
| 14 | NOBELZIN® | Mar-17 | hypozincemia | In-house |
| 15 | RAPALIMUS® Gel | Jun-18 | tuberous sclerosis-associated skin lesions | Osaka Univ/ In-house |
| 16 | TITANBRIDGE® (medical device) |
Jul-18 | adductor spasmodic dysphonia | TRI (Translational Research Center for Medical Innovation)/ Kumamoto Univ |
| 17 | JEMINA® | Oct-18 | dysmenorrhea | In-house |
| 18 | RETYMPA® | Dec-19 | tympanic perforation | TRI/ Kaken |
| 19 | Melatobel® | Jun-20 | Sleep-onset difficulty associated with neurodevelopmental disorder in children | In-house |
| 20 | RAPALIMUS® | Sep-21 | refractory lymphatic disease [lymphangioma (lymphatic malformation), lymphangiomatosis, Gorham's disease, lymphangiectasia] | Gifu Univ |
| 21 | Unitalc® | Mar-22 | Inoperable Secondary Intractable Pneumothorax | Nagoya Medical Center |
| 22 | LUNABELL®LD/ULD | Mar-22 | Coordinating the Timing of Initiation of Modulated Ovarian Stimulation in Assisted Reproductive Technology. | - |
| 23 | JEMINA® | Mar-22 | Coordinating the Timing of Initiation of Modulated Ovarian Stimulation in Assisted Reproductive Technology. | - |
- Research and Development